trial

Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1

NCTId NCT03507127
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 5 (actual)
Sponsored by Brown University
Primary completion 2019-06-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
5 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2018-05-01
Primary completion
2019-06-30
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Varenicline

Sponsors

Brown UniversityLead Sponsor

Investigators

1
Jennifer Tidey, PhDPrincipal Investigator

Sites

1 total
Providence, United States

Linked catalysts

1
Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia — primary completion2019-06-30

Facts & assertions

4 sourced
Enrollment
5
Phase
PHASE2
Primary Completion Date
2019-06-30
Status
TERMINATED
relationships
The graph out of here
drug
Varenicline
drug
lead_sponsor
Brown University
company
indication
Tobacco Use Disorder
indication
Tobacco Dependence
indication
investigator
Jennifer Tidey, PhD
person